ClinicalTrials.gg
CompletedNCT00511238Updated Aug 31, 2017Results posted

Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma

A Phase 2 interventional study of carfilzomib and carfilzomib in Multiple Myeloma, sponsored by Amgen. Completed at 34 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-31.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
312
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
12th of 113
312 · median 54
Started
2007
with 2 others
Phase 2
50 of 113
6 open now
Registered
2nd of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 12th largest by enrollment, is one of 3 that started in 2007, is one of 50 in phase 2, and was the 2nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma.

Patients must have received prior treatment with bortezomib and either thalidomide or lenalidomide and be refractory to their last treatment.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Onyx
  • PR171
  • carfilzomib
  • multiple myeloma
  • relapsed
  • refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Disease Related

    • Multiple myeloma
    • Subjects must have defined as one of the following:

      • Serum M-protein ≥ 1 g/dL
      • Urine M-protein ≥ 200 mg/24 hours
      • Serum FLC ≥ 10 mg/dL with abnormal ratio (A0 Only)
      • Quantitative immunoglobulin levels using nephelometry or turbidometry (only if protein electrophoresis was felt to be unreliable for M-protein measurement) (A0 Only)
    • Subjects must have been responsive (i.e., achieved an MR or better) to , standard of care therapy
    • to the most recently received therapy. Refractory disease is defined as ≤ 25% response or progression during therapy or within 60 days after completion of therapy.
    • Subjects must have received ≥ 2 prior regimens for relapsed disease. Induction therapy and stem cell transplant will be considered as one regimen (A1 Only)
    • Subjects must have received prior treatment with bortezomib, and either thalidomide or lenalidomide
    • Subjects must have received an alkylating agent either alone or in combination with other myeloma treatments (history of stem cell transplant is acceptable) (A1 Only)
    • Subjects must have received an anthracycline either alone or in combination with other myeloma treatments, unless not clinically indicated (A1 Only)
  • Demographic

    • Males and females > 18 years of age
    • of more than three months
    • (ECOG) Performance Status of 0-2
  • Laboratory

    • Adequate hepatic function, with less than 2.0 times the , and and ALT of less than 3.0 times the upper limit of normal
    • Uric acid within normal range (A0 Only)
    • Total white blood cell (WBC) count ≥ 2.0 × 109/L, (ANC) ≥ 1.0 × 109/L, ≥ 8.0 g/dL, and count ≥ 50.0 × 109/L (A0 Only)
    • Absolute neutrophil count > 1,000/mm3, hemoglobin > 8.0 g/dL, and platelet count > 50,000/mm3 (A1 Only)

      • Subjects should be platelet transfusion independent
      • Screening ANC should be independent of G-CSF or GM-CSF support for ≥ 1 week and of pegylated G-CSF for ≥ 2 weeks
      • Subjects may receive red blood cell (RBC) or platelet transfusions or receive supportive care such as erythropoietin and darbepoetin in accordance with institutional guidelines
    • Calculated and measured of ≥ 30 mL/minute, calculated using the formula of Cockcroft and Gault [(140 - Age) X Mass (kg) / (72 X Creatinine mg/dL)]. Multiply result by 0.85 if female.
  • Ethical / Other

    • Written in accordance with federal, local, and institutional guidelines
    • Female subjects of must have a negative serum pregnancy test within seven days of the first dose and agree to use dual methods of during and for 3 months following last dose of drug. Post menopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from a pregnancy test. Male subjects must use an effective barrier method of contraception during study and for 3 months following the last dose if sexually active with a female of child-bearing potential.

Exclusion criteria

Exclusion Criteria:

  • Disease Related

    • Multiple Myeloma IgM (A1 Only)
    • Subjects who failed to achieve at least a confirmed MR(≥ 25% reduction in M-protein for ≥ 6 weeks) (A1 Only)
    • Subjects with non-secretory multiple myeloma, defined as \< 1 g/dL M-protein in serum and \< 200 mg/24 hr M-protein in urine
    • Subjects with disease measurable only by serum free light chain (SFLC) analysis (A1 Only)
    • therapy (prednisone > 10 mg/day orally or equivalent) within the last three weeks
    • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
    • Plasma cell leukemia
    • Chemotherapy with approved or investigative anticancer therapeutics including steroid therapy within the three weeks prior to first dose
    • Radiation therapy or immunotherapy in the previous four weeks; localized radiation therapy within 1 week prior to first dose
    • Participation in an therapeutic study within three weeks or within five drug half-lives (t1/2) prior to Day 1, whichever time is greater
    • Prior treatment with carfilzomib
  • Concurrent Conditions

    • Major surgery within three weeks before Day 1
    • Congestive heart failure ( class III to IV), symptomatic cardiac ischemia, cardiomyopathy, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction in the previous six months, \< 40
    • Acute active infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first dose
    • Known or suspected infection or subjects who are HIV seropositive
    • Active hepatitis A,B,or C infection
    • Non-hematologic within the past three years except a) adequately treated basal cell or squamous cell skin cancer, b) carcinoma in situ of the cervix, or c) prostate cancer \<Gleason Grade 6 with stable PSA
    • Subjects with treatment related myelodysplastic syndrome
    • Significant neuropathy (Grade 3, 4 or Grade 2 with pain) at the time of study initiation
    • Subjects in whom the required program of oral and intravenous fluid hydration is , e.g., due to pre-existing pulmonary, cardiac or renal impairment (A1 Only)
    • Subjects with known or suspected amyloidosis (A1 Only)
    • Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis (A1 Only)
    • Any medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give (A1 Only)
  • Ethical / Other

    • Female subjects who are pregnant or lactating
    • Serious psychiatric or medical conditions that could interfere with treatment
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
312 participants (actual)

Study arms

  • Experimental
    carfilzomib (A0)

    Drug: carfilzomib

  • Experimental
    carfilzomib (A1)

    Drug: carfilzomib

Interventions

  • Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.

    Also known as: PR-171, PR171, Kyprolis® (carfilzomib) for Injection

  • Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.

    Also known as: PR-171, PR171, Kyprolis® (carfilzomib) for Injection

06

What researchers measure

Primary outcomes

  1. Best Overall Response Rate (ORR)

    For both A0 and A1, to evaluate the best overall response rate (stringent complete response \[sCR\]+ complete response \[CR\]+ very good partial response \[VGPR\]+ partial response \[PR\]) in patients with multiple myeloma who had previously received bortezomib and either thalidomide or lenalidomide, had relapsed after two or more therapies, and were refractory to the most recently received therapy

    Time frame: A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.

Secondary outcomes

  1. Clinical Benefit Response (CBR) (A0 Only)

    sCR, CR, VGPR, PR, and minimal response (MR)

    Time frame: Response assessments same as described in primary outcome measure

  2. Clinical Benefit Response (CBR) (A1 Only)

    sCR, CR, VGPR, PR, and minimal response (MR)

    Time frame: Response assessments same as described in primary outcome measure

  3. Duration of Response (A0 Only)

    Duration of response (DOR) was calculated separately for subjects with clinical benefit response or overall response. DOR is defined as the time from first evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death.

    Time frame: Response assessments same as described in primary outcome measure

  4. Duration of Response (A1 Only)

    Duration of response (DOR) was calculated separately for subjects with clinical benefit response or overall response. DOR is defined as the time from first evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death.

    Time frame: Response assessments same as described in primary outcome measure

  5. Time to Progression (A0 Only)

    Time to progression (TTP) is defined as the time from the study entry (first dose of carfilzomib) to disease progression.

    Time frame: Response assessments same as described in primary outcome measure

  6. Time to Progression (A1 Only)

    Time to progression (TTP) is defined as the time from the study entry (first dose of carfilzomib) to disease progression.

    Time frame: Response assessments same as described in primary outcome measure

  7. Progression-free Survival (A0 Only)

    The PFS was defined as the time from the start of treatment to progressive disease (PD) determined by PI or until death.

    Time frame: Response assessments same as described in primary outcome measure

  8. Progression-free Survival (A1 Only)

    The PFS was defined as the time from the start of treatment to progressive disease (PD) determined by PI or until death.

    Time frame: Response assessments same as described in primary outcome measure

  9. Overall Survival (A1 Only)

    The time from start of treatment to death due to any cause OS was to be censored on the date the subject was last known to be alive for those who were alive or lost to follow-up as of a data analysis cutoff date.

    Time frame: Patients were to be followed by telephone contact for disease progression and OS every 3 months after study discontinuation for the first year and every 6 months thereafter for up to 2 years

07

Results

Posted Dec 9, 2013

Participant flow

Results of this study are reported in 2 parts, depending on whether a patient was enrolled and treated under the original protocol (referred to as 'A0') or under Amendment 1 and subsequent amendments (referred to as 'A1').

Participant flow — Overall Study
MilestoneCarfilzomib (A0)Carfilzomib (A1)
Started46266
Completed440
Not completed42226
Withdrew: Adverse event1333
Withdrew: Withdrawal by subject222
Withdrew: Progressive disease23157
Withdrew: Various reasons414

Outcome measures

PrimaryBest Overall Response Rate (ORR)

For both A0 and A1, to evaluate the best overall response rate (stringent complete response \[sCR\]+ complete response \[CR\]+ very good partial response \[VGPR\]+ partial response \[PR\]) in patients with multiple myeloma who had previously received bortezomib and either thalidomide or lenalidomide, had relapsed after two or more therapies, and were refractory to the most recently received therapy

Time frame:
A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.
Reported as:
Number · % of participants w/ PR or better
Best Overall Response Rate (ORR)
% of participants w/ PR or betterCarfilzomib (A0)Carfilzomib (A1)
Best Overall Response Rate (ORR)16.7 (6.97 to 31.36)23.7 (18.67 to 29.42)
SecondaryClinical Benefit Response (CBR) (A0 Only)

sCR, CR, VGPR, PR, and minimal response (MR)

Time frame:
Response assessments same as described in primary outcome measure
Reported as:
Number · participants
Clinical Benefit Response (CBR) (A0 Only)
participantsCarfilzomib (A0)
Clinical Benefit Response (sCR+CR+VGPR+PR+MR)10
Complete Response0
Very Good Partial Response0
Partial Response7
Minimal Response3
SecondaryClinical Benefit Response (CBR) (A1 Only)

sCR, CR, VGPR, PR, and minimal response (MR)

Time frame:
Response assessments same as described in primary outcome measure
Reported as:
Number · participants
Clinical Benefit Response (CBR) (A1 Only)
participantsCarfilzomib (A1)
Clinical Benefit Response (sCR+CR+VGPR+PR+MR)95
Complete Response1
Very Good Partial Response13
Partial Response47
Minimal Response34
SecondaryDuration of Response (A0 Only)

Duration of response (DOR) was calculated separately for subjects with clinical benefit response or overall response. DOR is defined as the time from first evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death.

Time frame:
Response assessments same as described in primary outcome measure
Reported as:
Median · days
Duration of Response (A0 Only)
daysCarfilzomib (A0) for (ORR)
Duration of Response (A0 Only)219 (57 to NA)
SecondaryDuration of Response (A1 Only)

Duration of response (DOR) was calculated separately for subjects with clinical benefit response or overall response. DOR is defined as the time from first evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death.

Time frame:
Response assessments same as described in primary outcome measure
Reported as:
Median · months
Duration of Response (A1 Only)
monthsCarfilzomib (A1) for (ORR)Carfilzomib (A1) for (CBR)
Duration of Response (A1 Only)7.8 (5.6 to 9.2)8.3 (6.5 to 9.7)
SecondaryTime to Progression (A0 Only)

Time to progression (TTP) is defined as the time from the study entry (first dose of carfilzomib) to disease progression.

Time frame:
Response assessments same as described in primary outcome measure
Reported as:
Median · months
Time to Progression (A0 Only)
monthsCarfilzomib (A0)
Time to Progression (A0 Only)3.5 (2.4 to 6.7)
SecondaryTime to Progression (A1 Only)

Time to progression (TTP) is defined as the time from the study entry (first dose of carfilzomib) to disease progression.

Time frame:
Response assessments same as described in primary outcome measure
Reported as:
Median · months
Time to Progression (A1 Only)
monthsCarfilzomib (A1)
Time to Progression (A1 Only)3.9 (2.8 to 4.8)
SecondaryProgression-free Survival (A0 Only)

The PFS was defined as the time from the start of treatment to progressive disease (PD) determined by PI or until death.

Time frame:
Response assessments same as described in primary outcome measure
Reported as:
Median · months
Progression-free Survival (A0 Only)
monthsCarfilzomib (A0)
Progression-free Survival (A0 Only)3.5 (2.4 to 6.7)
SecondaryProgression-free Survival (A1 Only)

The PFS was defined as the time from the start of treatment to progressive disease (PD) determined by PI or until death.

Time frame:
Response assessments same as described in primary outcome measure
Reported as:
Median · months
Progression-free Survival (A1 Only)
monthsCarfilzomib (A1)
Progression-free Survival (A1 Only)3.7 (2.8 to 4.6)
SecondaryOverall Survival (A1 Only)

The time from start of treatment to death due to any cause OS was to be censored on the date the subject was last known to be alive for those who were alive or lost to follow-up as of a data analysis cutoff date.

Time frame:
Patients were to be followed by telephone contact for disease progression and OS every 3 months after study discontinuation for the first year and every 6 months thereafter for up to 2 years
Reported as:
Number · months
Overall Survival (A1 Only)
monthsCarfilzomib (A1) - Safety PopulationCarfilzomib (A1) - Response-evaluable Population
Overall Survival (A1 Only)15.4 (12.5 to 19.0)15.6 (13.0 to 19.2)

Adverse events

Collected over All adverse events (AEs) should be reported from the time the subject signs consent through 30 days post-last dose of study drug or initiation of a new anti-cancer therapy, whichever occurs first.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carfilzomib (A0)—20/46 (43.5%)46/46 (100%)
Carfilzomib (A1)—126/266 (47.4%)266/266 (100%)
Most frequent serious events
Showing 10 of 104
Most frequent serious events
EventCarfilzomib (A0)Carfilzomib (A1)
Disease progressionGeneral disorders5/4616/266
PneumoniaInfections and infestations5/4623/266
Renal failure acuteRenal and urinary disorders4/469/266
Cardiac failure congestiveCardiac disorders2/468/266
BacteraemiaInfections and infestations2/461/266
HypercalcaemiaMetabolism and nutrition disorders2/466/266
Tumour lysis syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/460/266
PyrexiaGeneral disorders1/468/266
Pathological fractureMusculoskeletal and connective tissue disorders1/468/266
Spinal cord compressionNervous system disorders0/466/266
Most frequent other events
Showing 10 of 106
Most frequent other events
EventCarfilzomib (A0)Carfilzomib (A1)
AnaemiaBlood and lymphatic system disorders34/46122/266
FatigueGeneral disorders32/46130/266
ThrombocytopeniaBlood and lymphatic system disorders23/46103/266
NauseaGastrointestinal disorders16/46119/266
Upper respiratory tract infectionInfections and infestations17/4671/266
LymphopeniaBlood and lymphatic system disorders16/4662/266
Blood creatinine increasedInvestigations16/4667/266
HypocalcaemiaMetabolism and nutrition disorders16/4614/266
DyspnoeaRespiratory, thoracic and mediastinal disorders13/4690/266
DiarrhoeaGastrointestinal disorders15/4686/266

Baseline characteristics

Safety population: The safety population consists of all enrolled patients who received at least 1 dose of carfilzomib.

Age, Categorical
Age, Categorical(Participants)Carfilzomib (A0)Carfilzomib (A1)Total
<=18 years000
Between 18 and 65 years26146172
>=65 years20120140
Sex: Female, Male
Sex: Female, Male(Participants)Carfilzomib (A0)Carfilzomib (A1)Total
Female21111132
Male25155180
08

Study locations

34 sites
  • Southern Cancer Center
    Mobile, Alabama 36608, United States
  • Mayo Clinic Scottsdale
    Scottsdale, Arizona 85259, United States
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Scripps Clinic
    La Jolla, California 92037, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33905, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Emory University Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Northwestern Universtiy
    Chicago, Illinois 60605, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • St. Vincent Catholic Medical Center
    New York, New York 10011, United States
  • Wake Forest University
    Winston-Salem, North Carolina 27157, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Oncology & Hematology Care
    Cincinnati, Ohio 45236, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Northwest Cancer Center
    Houston, Texas 77090, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • University of Calgary
    Calgary, Alberta T2N 4N2, Canada
  • University of Alberta, Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Leukemia/BMT Program of BC
    Vancouver, British Columbia V5Z 1M9, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2C1, Canada
  • Royal Victoria Hospital
    Montreal, Quebec H3A 1A1, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
09

References and documents

Publications

  • Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25. PubMed 22833546 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Nov 2010 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2007
First posted
Aug 3, 2007
Start
Aug 2007
Primary completionActual
Nov 2010
CompletionActual
Oct 2012
Results first posted
Dec 9, 2013
Last update
Aug 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00511238
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 3, 2007
Start date
Aug 2007
Primary completion
Nov 2010
Completion
Oct 2012
Results posted
Dec 9, 2013
Last update
Aug 31, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion